821 related articles for article (PubMed ID: 30427062)
21. Dietary Modulation of Intestinal Microbiota: Future Opportunities in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Fan Y; Zhang J
Front Microbiol; 2019; 10():740. PubMed ID: 31040833
[TBL] [Abstract][Full Text] [Related]
22. The "Gut Feeling": Breaking Down the Role of Gut Microbiome in Multiple Sclerosis.
Freedman SN; Shahi SK; Mangalam AK
Neurotherapeutics; 2018 Jan; 15(1):109-125. PubMed ID: 29204955
[TBL] [Abstract][Full Text] [Related]
23. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.
Cekanaviciute E; Yoo BB; Runia TF; Debelius JW; Singh S; Nelson CA; Kanner R; Bencosme Y; Lee YK; Hauser SL; Crabtree-Hartman E; Sand IK; Gacias M; Zhu Y; Casaccia P; Cree BAC; Knight R; Mazmanian SK; Baranzini SE
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10713-10718. PubMed ID: 28893978
[TBL] [Abstract][Full Text] [Related]
24. The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?
Parodi B; Kerlero de Rosbo N
Front Immunol; 2021; 12():718220. PubMed ID: 34621267
[TBL] [Abstract][Full Text] [Related]
25. Interaction of the Gut Microbiome and Immunity in Multiple Sclerosis: Impact of Diet and Immune Therapy.
Yadav SK; Ito K; Dhib-Jalbut S
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834203
[TBL] [Abstract][Full Text] [Related]
26. Role of microbiota short-chain fatty acids in the pathogenesis of autoimmune diseases.
Rasouli-Saravani A; Jahankhani K; Moradi S; Gorgani M; Shafaghat Z; Mirsanei Z; Mehmandar A; Mirzaei R
Biomed Pharmacother; 2023 Jun; 162():114620. PubMed ID: 37004324
[TBL] [Abstract][Full Text] [Related]
27. Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis.
Bianchimano P; Britton GJ; Wallach DS; Smith EM; Cox LM; Liu S; Iwanowski K; Weiner HL; Faith JJ; Clemente JC; Tankou SK
Microbiome; 2022 Oct; 10(1):174. PubMed ID: 36253847
[TBL] [Abstract][Full Text] [Related]
28. The role of short-chain fatty acids in microbiota-gut-brain communication.
Dalile B; Van Oudenhove L; Vervliet B; Verbeke K
Nat Rev Gastroenterol Hepatol; 2019 Aug; 16(8):461-478. PubMed ID: 31123355
[TBL] [Abstract][Full Text] [Related]
29. The Role of Gut-derived Short-Chain Fatty Acids in Multiple Sclerosis.
Saadh MJ; Ahmed HM; Alani ZK; Al Zuhairi RAH; Almarhoon ZM; Ahmad H; Ubaid M; Alwan NH
Neuromolecular Med; 2024 Apr; 26(1):14. PubMed ID: 38630350
[TBL] [Abstract][Full Text] [Related]
30. Role of microbiota-derived short-chain fatty acids in nervous system disorders.
Mirzaei R; Bouzari B; Hosseini-Fard SR; Mazaheri M; Ahmadyousefi Y; Abdi M; Jalalifar S; Karimitabar Z; Teimoori A; Keyvani H; Zamani F; Yousefimashouf R; Karampoor S
Biomed Pharmacother; 2021 Jul; 139():111661. PubMed ID: 34243604
[TBL] [Abstract][Full Text] [Related]
31. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication.
Silva YP; Bernardi A; Frozza RL
Front Endocrinol (Lausanne); 2020; 11():25. PubMed ID: 32082260
[TBL] [Abstract][Full Text] [Related]
32. Gut microbiome in multiple sclerosis: The players involved and the roles they play.
Shahi SK; Freedman SN; Mangalam AK
Gut Microbes; 2017 Nov; 8(6):607-615. PubMed ID: 28696139
[TBL] [Abstract][Full Text] [Related]
33. Gut microbiome and multiple sclerosis: New insights and perspective.
Esmaeil Amini M; Shomali N; Bakhshi A; Rezaei S; Hemmatzadeh M; Hosseinzadeh R; Eslami S; Babaie F; Aslani S; Torkamandi S; Mohammadi H
Int Immunopharmacol; 2020 Nov; 88():107024. PubMed ID: 33182024
[TBL] [Abstract][Full Text] [Related]
34. Oxymatrine ameliorates experimental autoimmune encephalomyelitis by rebalancing the homeostasis of gut microbiota and reducing blood-brain barrier disruption.
Zhang ML; Li WX; Wang XY; Wu YL; Chen XF; Zhang H; Yang LQ; Wu CZ; Zhang SQ; Chen YL; Feng KR; Wang B; Niu L; Kong DX; Tang JF
Front Cell Infect Microbiol; 2022; 12():1095053. PubMed ID: 36710971
[TBL] [Abstract][Full Text] [Related]
35. Microbial dysbiosis and lack of SCFA production in a Spanish cohort of patients with multiple sclerosis.
Moles L; Delgado S; Gorostidi-Aicua M; Sepúlveda L; Alberro A; Iparraguirre L; Suárez JA; Romarate L; Arruti M; Muñoz-Culla M; Castillo-Triviño T; Otaegui D;
Front Immunol; 2022; 13():960761. PubMed ID: 36325343
[TBL] [Abstract][Full Text] [Related]
36. Multiple sclerosis: Possibility of a gut environment-induced disease.
Sato W; Yamamura T
Neurochem Int; 2019 Nov; 130():104475. PubMed ID: 31152766
[TBL] [Abstract][Full Text] [Related]
37. The second brain: The connection between gut microbiota composition and multiple sclerosis.
Farshbafnadi M; Agah E; Rezaei N
J Neuroimmunol; 2021 Nov; 360():577700. PubMed ID: 34482269
[TBL] [Abstract][Full Text] [Related]
38. Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis.
Zeng Q; Junli Gong ; Liu X; Chen C; Sun X; Li H; Zhou Y; Cui C; Wang Y; Yang Y; Wu A; Shu Y; Hu X; Lu Z; Zheng SG; Qiu W; Lu Y
Neurochem Int; 2019 Oct; 129():104468. PubMed ID: 31108132
[TBL] [Abstract][Full Text] [Related]
39. Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?
Adamczyk-Sowa M; Medrek A; Madej P; Michlicka W; Dobrakowski P
J Immunol Res; 2017; 2017():7904821. PubMed ID: 28316999
[No Abstract] [Full Text] [Related]
40. Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.
Ordoñez-Rodriguez A; Roman P; Rueda-Ruzafa L; Campos-Rios A; Cardona D
Int J Environ Res Public Health; 2023 Mar; 20(5):. PubMed ID: 36901634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
